ÂÜÀòÂÒÂ×

Kimberly L. Blackwell is the Chief Medical Officer at Tempus Labs.

As one of the nation’s leading breast cancer researchers, Dr Blackwell has played a role in developing therapies that represent revolutionary non-chemotherapy based approaches for treating breast cancer. This work led to Dr Blackwell’s inclusion on TIME magazine’s 2013 list of the 100 most influential people in the world. Her work contributed to the development of lapatinib and T-DM1 for the treatment of HER2+ breast cancer. Dr Blackwell has served as the principal or co-principal investigator for over 50 cancer clinical trials, including two registration studies for biosimilar G-CSF. After 24 years at the Duke Cancer Institute, she joined Eli Lilly as Vice President of Early Phase Oncology and Immuno-oncology from 2018-2020 where she lead the clinical development teams for promising early stage therapeutics. Most recently, she joined Tempus Labs as Chief Medical Officer where she oversees precision medicine approaches to improve cancer care and guide therapeutic drug development and discovery.